Pulmozyme Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience
CONCLUSIONS AND RELEVANCE: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.PMID:35184602 | DOI:10.1177/10600280221077383 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 21, 2022 Category: Drugs & Pharmacology Authors: Christopher Francis Janowak Bradley Robert Becker Carolyn Dosen Philpott Amy Teres Makley Eric William Mueller Christopher Allen Droege Molly Elizabeth Droege Source Type: research

Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society
ConclusionClinical features indicative of severe form of CF are associated with increased risk of COVID-19 hospitalization. SARS-CoV-2 infected patients do not experience a deterioration of respiratory function. (Source: Infection)
Source: Infection - December 7, 2021 Category: Infectious Diseases Source Type: research

Longitudinal SF6 multiple breath washout in infants and toddlers with cystic fibrosis
Conclusion: Longitudinal SF6MBW in NBS infants and toddlers with CF demonstrated intermittent lung function impairment in the majority, and an overall gradual worsening, which calls for even earlier start of treatments such as inhaled hypertonic saline and CFTR-modulators. (Source: European Respiratory Journal)
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Sandvik, R. M., Schmidt, M. N., Kragh, M. V., Voldby, C., Buchvald, F., Pressler, T., Lindblad, A., Skov, M., Gustafsson, P., Nielsen, K. G. Tags: Paediatric cystic fibrosis (CF) Source Type: research

Evaluation of the tolerability of the dornase alfa based on the results of a multicenter scientific program of post-marketing use of the medicine
Conclusions: The Tigeraza® (Generium, Russia) was well tolerated by patients with CF in 93.4% of cases and the frequency of ADRs were less than 1: 1000, which did not exceed the frequency of ADRs with the use of the Pulmozyme® (F. Hoffmann-La Roche Ltd., Switzerland). (Source: European Respiratory Journal)
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Kondratyeva, E., Shadrina, V., Furman, E., Voronkova, A., Sherman, V., Zhekaite, E., Simanova, O., Malakhov, A., Mukhina, M., Yakushina, E., Vysokolova, O., Ilyenkova, N., Trishina, S., Pinegina, J., Safonova, T., Vasilyeva, E., Golubtsova, O. Tags: Adult cystic fibrosis (CF) Source Type: research

Coronavirus infection (Covid - 19) in children with cystic fibrosis in the Russian Federation
Conclusion: Despite the most patients with CF had asymptomatic and mild cours COVID-19 - 28 (93.3%), versus the age-matched general population, children with CF have a higher incidence of SARS-CoV-2 infection. Fever, increased cough and fatigue were more common in patients with COVID-19 with CF. (Source: European Respiratory Journal)
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Zhekaite, E., Kondratyeva, E., Sherman, V., Simonova, O., Gorinova, Y., Voronkova, A. Tags: Epidemiology Source Type: research

Late Breaking Abstract - Short duration high intensity intrapleural Alteplase with Pulmozyme in pleural infection management - a single centre experience
Conclusion: Modified regimen of 16mg t-PA and 5mg DNase is an effective therapy of complex pleural infection evidenced by radiological and biochemical improvement.Reference: 1.Rahman NM et.al NEJM.2011;518-26 (Source: European Respiratory Journal)
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Cheong, X. K., Hamid, M. F. A., Ban, A. Y.-L., Ng, B. H., Nik Abeed, N. N., Nik Ismail, N. A., Nik Fuad, N. F., Syed Zakaria, S. Z., Ghan, S. L. Tags: Respiratory infections and bronchiectasis Source Type: research

Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19
ConclusionTreatment with dornase alfa was associated with improved oxygenation and decreased DNA : MPO complexes in BALF. The positive effects, however, were limited to the time of drug delivery. These data suggest that degradation of extracellular DNA associated with NETs or other structures by inhaled dornase alfa can be beneficial. We propose a more extensive clinical trial is warranted.Clinical Trial RegistrationClinicalTrials.gov, Identifier: NCT04402970. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - October 20, 2021 Category: Allergy & Immunology Source Type: research

Variation in treatment preferences of pulmonary exacerbations among Australian and New Zealand cystic fibrosis physicians
CONCLUSIONS: Variation exists among CF physicians in their preferred choice of primary antibiotic and use of dornase alfa. These preferences are driven by professional opinion, possibly reflecting a lack of evidence to base policy recommendations. Evidence from high-quality clinical trials is needed to inform physician decision making.PMID:34266854 | DOI:10.1136/bmjresp-2021-000956 (Source: Respiratory Care)
Source: Respiratory Care - July 16, 2021 Category: Respiratory Medicine Authors: Grace Currie Anna Tai Tom Snelling Andr é Schultz Source Type: research